NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.14
+3.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.8M | 84.0M | 54.5M | 77.0M | 38.6M |
| Cost of Revenue | 97.6M | 18.9M | 221.6M | 189.1M | 184.5M |
| Gross Profit | (60.9M) | 65.1M | (167.1M) | (112.2M) | (145.9M) |
| Operating Expenses | |||||
| R&D Expense | 338.8M | 308.2M | 221.6M | 189.1M | 184.5M |
| SG&A Expense | 57.0M | 52.7M | 45.9M | 42.9M | 38.0M |
| General & Admin Expense | 57.0M | 52.7M | 45.9M | 42.9M | 38.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (95.5M) | (10.1M) | (221.6M) | (189.1M) | (184.5M) |
| Total Operating Expenses | 300.3M | 350.8M | 45.9M | 42.9M | 38.0M |
| Cost and Expenses | 397.9M | 369.6M | 267.6M | 232.1M | 222.5M |
| Operating Income (EBIT) | (361.2M) | (285.7M) | (213.0M) | (155.1M) | (183.9M) |
| Non-Operating | |||||
| Interest Income | 19.6M | 22.0M | 19.7M | 11.1M | 3.5M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 19.6M | 22.0M | 19.7M | 11.1M | 3.5M |
| Other Non-Op Income/Expense | 19.6M | 22.0M | 19.7M | 11.1M | 3.5M |
| Non-Operating Income (excl Interest) | (19.6M) | (22.0M) | (19.7M) | (11.1M) | (3.5M) |
| EBT (Pre-Tax Income) | (341.6M) | (263.7M) | (193.3M) | (143.9M) | (180.4M) |
| Income Tax Expense | (271.0K) | 760.0K | 270.0K | — | — |
| Bottom Line | |||||
| Net Income | (341.4M) | (264.5M) | (193.6M) | (143.9M) | (180.4M) |
| Earnings from Cont. Ops | (341.4M) | (264.5M) | (193.6M) | (143.9M) | (180.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (341.4M) | (264.5M) | (193.6M) | (143.9M) | (180.4M) |
| Per Share | |||||
| Basic EPS | ($3.45) | ($3.05) | ($2.88) | ($2.65) | ($3.71) |
| Diluted EPS | ($3.45) | ($3.05) | ($2.88) | ($2.65) | ($3.71) |
| Revenue Per Share | $0.33 | $0.97 | $0.81 | $1.42 | $0.79 |
| Shares | |||||
| Basic Shares Outstanding | 111.1M | 86.7M | 67.1M | 54.3M | 48.6M |
| Diluted Shares Outstanding | 111.1M | 86.7M | 67.1M | 54.3M | 48.6M |
| Profitability Metrics | |||||
| EBITDA | (319.7M) | (244.8M) | (185.3M) | (137.8M) | (176.2M) |
| D&A | 21.9M | 18.9M | 8.0M | 6.1M | 4.1M |
| EBIT | (341.6M) | (263.7M) | (193.3M) | (143.9M) | (180.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of May 1, 2026